Below is a summary of the latest health news.
Pfizer is applying to Swissmedic for approval of another COVID-19 vaccine
Pfizer said Thursday it had submitted an application to Swissmedic for approval of another bivalent COVID-19 vaccine. The ready-to-use injection dispersion contained both messenger RNA (mRNA) from the original Pfizer/BioNTech COVID-19 vaccine and mRNA encoding the spike protein of omicron variants BA.4 and BA.5, Pfizer said.
Scammers likely stole $45.6 billion from US Unemployment Insurance program in COVID
Scammers likely stole $45.6 billion from the United States’ unemployment insurance program during the COVID-19 pandemic using tactics such as using deceased people’s Social Security numbers, a federal watchdog said Thursday. About a year ago, nearly $16 billion in potential fraud was identified. The report, issued Thursday by the US Department of Labor’s inspector general, identified “a $29.6 billion increase in potentially fraudulent payments.”
The US FDA panel recommends Ferring’s stool transplant therapy
A panel of U.S. Food and Drug Administration advisers voted in favor of Ferring Pharmaceuticals’ stool transplant-based therapy to reduce recurrent infections caused by a bacterium called C. difficile. The therapy is based on the concept of replenishing the good gut bacteria with samples of microbes distilled from the feces of healthy donors, in this case through an enema.
Uganda has so far confirmed seven Ebola cases, one death
Uganda has confirmed seven cases of Ebola, including in a man who died this week, and seven other deaths are being investigated as suspected cases from a strain for which authorities don’t yet have a vaccine, officials said Thursday. The 24-year-old deceased had developed a high fever, diarrhea and abdominal pain and was vomiting blood. After initially being treated for malaria, he was diagnosed with the Sudan strain of the Ebola virus.
Humana, CVS Among Companies Looking to Buy Cano Health – Reports
Humana and CVS Health are among several companies looking to buy senior care facility operator Cano Health, according to media reports Thursday, sending Cano’s shares up about 50%. The talks are serious and a deal to buy Cano could be finalized in the next few weeks, the Wall Street Journal said Thursday, citing people familiar with the matter.
GSK targets Spero’s experimental drug for urinary tract infections and takes over
British drugmaker GSK said on Thursday it would take a stake in Spero Therapeutics under a licensing agreement for the US drug developer’s experimental antibiotic for complicated urinary tract infections (cUTI). GSK will pay US$66 million upfront for oral antibiotic Tebipenem HBr and will purchase US$9 million of Spero stock as part of the transaction.
Pfizer is delivering up to 6 million COVID pill courses to low-income countries
Pfizer Inc announced Thursday that it will supply up to 6 million courses of its COVID-19 antiviral treatment to the NGO Global Fund for low- and middle-income countries trying to address global disparities in the COVID response. The company said Paxlovid treatment courses will be available for procurement this year through the Global Fund’s COVID-19 Response Mechanism for 132 low- and middle-income countries, subject to local regulatory approvals.
COVID increases risk of long-term brain injury, large US study shows
People who have had COVID-19 are at higher risk of a variety of brain injuries a year later than people who never had the coronavirus, a finding that could affect millions of Americans, U.S. researchers reported Thursday. The year-long study, published in Nature Medicine, evaluated brain health in 44 different disorders using unidentified medical records from millions of US veterans.
US FDA panel votes against Spectrum’s lung cancer drug
Advisors to the U.S. Food and Drug Administration voted Thursday against recommending Spectrum Pharmaceuticals’ investigational drug to treat patients with a form of non-small cell lung cancer. The FDA panel voted 9-4 against the oral drug poziotinib, citing low efficacy, high levels of toxicity and lack of dose optimization.
Novartis takes US drug patent case to Supreme Court
Novartis AG plans to ask the US Supreme Court to uphold a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling, the Swiss drugmaker said on Wednesday. The ruling meant HEC Pharma and other drugmakers would potentially be able to launch a generic version of 0.5 mg Gilenya shortly pending further legal action, it said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)